Table II.

Patterns of Failure Among the Patients with Group I Alv Rms Who Did Not Have An Amputation

Pt. No.; Age (years) + Gender	Primary Site, Size (cm); Stage	Regional Lymph Nodes at Diagnosis	Local RT Dose, Gray	Chemotherapy	Type of Failure; Time After Study Entry	Survival Status; Time After Study Entry
1; 12M	R Shoulder, 2; Stage 2	Clinical N0	0	VA	Local; 1.7 years	NED; 16.2 years+
2; 10M	L chest wall, 6.5; Stage 3	Clinical N0	0	VAC, Dox, Cpt	Local; 1.8 years	Dead, rafting accident; no tumor recurrence; 7.6 years
3; 2M	R neck, 4; Stage 1	Pathologic N0	0	VAC	Local; 0.7 year	NED; 5.9 years+
4; 4M	L lip, 3; Stage 1	Clinical N0	0	VAC, Etop, Ifos	Locoregional; 1.9 years	Dead of tumor; 3.7 years
5; 4F	R thigh, 3; Stage 2	Pathologic N0	41.4	VAC, Dox, Cpt	Regional; 4.6 years	NED; 9.6 years+
6; 1.4M	R thigh, 6; Stage 3	Pathologic N0	36; Ir192 Brachy- therapy	VAC	DM; 5.6 years	Dead of tumor; 7.6 years
7; 13F	L arm, 7.5; Stage 3	Clinical N0	41.6	VAC, Dox, Cpt	DM; 2.6 years	Dead after BMT; 3.2 years

Abbreviations: No., number; L, left; R, right; NED, no evidence of disease; RT, radiotherapy; N0, no lymph node involvement; VAC, vincristine, actinomycin D, cyclophosphamide; Dox, doxorubicin; Cpt, cisplatin; Etop, etoposide (VP-16); Ifos, ifosfamide; + alive at last contact; DM, distant metastasis (including lymph nodes proximal to regional lymph nodes, if applicable); BMT, bone marrow transplantation